

Cosentyx Rheum - UnoReady® 300 mg injection video - HCP

[Prescribing information](#)

Image



Image



## **Cosentyx® (secukinumab): UnoReady® 300 mg injection video**

Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.<sup>1</sup>

[Full indication for Cosentyx can be found here](#)

[Cosentyx Summary of Product Characteristics \(SmPC\) can be found here.](#)

---

Do not share screenshots or links to this website, video with patients, as this website is intended for healthcare professionals only. If you do wish to share a video with patients who have been prescribed Cosentyx, please share this link:

[pro.novartis.com/uk-en/public/medicines/rheumatology/cosentyx/patient-resources/unoready-injection-video](https://pro.novartis.com/uk-en/public/medicines/rheumatology/cosentyx/patient-resources/unoready-injection-video)

**This page contains a short 5-minute video demonstrating how to prepare and deliver Cosentyx with the UnoReady® pen.**

Image



**For a 300 mg dose, one 300 mg pen or two 150 mg pens are needed.**

For information on the Cosentyx SensoReady® 150 mg pen click [here](#).

**For UK Healthcare Professionals only.**

**Prescribing information is available on the top of the page where the video is hosted.**

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard).  
Adverse events should also be reported to Novartis via [uk.patientsafety@novartis.com](mailto:uk.patientsafety@novartis.com) or online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report).

If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com)

This video has been funded and developed by Novartis Pharmaceuticals UK Ltd.

UK | November 2023 | 305687

## VIDEO

This video has been funded and developed by Novartis Pharmaceuticals UK Ltd.

---

Image



Dosing

---

### **Therapeutic Indications<sup>1</sup>**

Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic

arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.<sup>1</sup>

AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; ERA; enthesitis-related arthritis; HS, hidradenitis suppurativa; JIA, juvenile idiopathic arthritis; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis.

## Reference

1. Cosentyx® (secukinumab) Summary of Product Characteristics.

UK | March 2025 | FA-11357167

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

### Source URL:

<https://www.pro.novartis.com/uk-en/medicines/rheumatology/cosentyx/resources/unoready-injection-video>